Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2 and RhoA

• Published in: Nature chemical biology Vol. 16; no. 4; pp. 400 - 407
• Main Authors: Bowling, Forrest Z., Salazar, Christian M., Bell, Justin A., Huq, Tahrima S., Frohman, Michael A., Airola, Michael V.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.04.2020; Nature Publishing Group
• Subjects: 631/45; 631/45/607; 631/535; 631/535/1266; 631/92/287/1192; Activation; Binding; Biochemical Engineering; Biochemistry; Bioorganic Chemistry; Cell Biology; Chemistry; Chemistry and Materials Science; Chemistry/Food Science; Crystal structure; Enzymatic activity; Hydrophobicity; Kinases; Lecithin; Lipids; Mapping; Membranes; Mutation; Phosphatidic acid; Phosphatidylcholine; Phosphatidylinositol 4,5-diphosphate; Phosphohistidine; Phospholipase; Phospholipase D1; Protein kinase C; Proteins; RhoA protein; Signal transduction; Substrates; Therapeutic applications; Thromboembolism; Thrombosis
• ISSN: 1552-4450; 1552-4469
• DOI: 10.1038/s41589-020-0499-8

The signal transduction enzyme phospholipase D1 (PLD1) hydrolyzes phosphatidylcholine to generate the lipid second-messenger phosphatidic acid, which plays roles in disease processes such as thrombosis and cancer. PLD1 is directly and synergistically regulated by protein kinase C, Arf and Rho GTPases, and the membrane lipid phosphatidylinositol-4,5-bisphosphate (PIP 2 ). Here, we present a 1.8 Å-resolution crystal structure of the human PLD1 catalytic domain, which is characterized by a globular fold with a funnel-shaped hydrophobic cavity leading to the active site. Adjacent is a PIP 2 -binding polybasic pocket at the membrane interface that is essential for activity. The C terminus folds into and contributes part of the catalytic pocket, which harbors a phosphohistidine that mimics an intermediate stage of the catalytic cycle. Mapping of PLD1 mutations that disrupt RhoA activation identifies the RhoA-PLD1 binding interface. This structure sheds light on PLD1 regulation by lipid and protein effectors, enabling rationale inhibitor design for this well-studied therapeutic target. A structural study of one of two human phospholipase D enzymes, hPLD1, helps define the determinants of substrate recognition, the highly regulated enzymatic activity, as well as activation by PIP 2 and RhoA.